KineMed and CHDI Foundation Extend Collaboration on Huntington's Disease Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – KineMed said this week that it has extended its collaboration with the CHDI Foundation on research into biomarkers for Huntington's disease.

Under the agreement the company will use its mass spec-based Dynamic Proteomics platform to perform global discovery of proteins linked to Huntington's with the ultimate goal of identifying biomarkers that can be used to monitor the efficacy of treatments for the disease, Patrizia Fanara, KineMed's vice president of neuroscience, told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.